---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-26-000043"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2026-07-22T21:03:59+00:00"
generated_at: "2026-07-22T21:06:06.667084+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics appoints Farrell Simon to Board of Directors

## Summary
- Farrell Simon appointed to Serina's Board effective July 22, 2026; will serve on Audit and Compensation Committees.
- Simon is Chief Commercial Officer at Trevi Therapeutics (TRVI), helped raise over $400M from top-tier investors.
- Previously spent a decade at Pfizer in senior commercial and strategic roles.
- Serina's SER-252 Phase 1b registrational study is double-blind, placebo-controlled, with single and multiple ascending doses in Parkinson's patients.
- Simon's experience in commercial strategy and business development expected to support Serina's POZ platform and SER-252 development.

## SEC filing metadata
- accession: 0001708599-26-000043
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2026-07-22T21:03:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000043/0001708599-26-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000043/ser-20260723xappointmentof.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-26-000043
- JSON: https://secwatch.observer/filing/0001708599-26-000043.json
- Plain text: https://secwatch.observer/filing/0001708599-26-000043.txt

## Key facts
- Executive change
  Farrell Simon was appointed as Member of the Board of Directors at Serina Therapeutics, Inc..
  - Action: appointed
  - Role: Member of the Board of Directors
  source text: On July 22, 2026, Serina Therapeutics, Inc. (the “Company”) issued a press release announcing the appointment of Farrell Simon, Pharm. D., to the Company’s Board of Directors, effective July 22, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000043/0001708599-26-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.